18 research outputs found
Recommended from our members
A window on the deep ocean: the special value of ocean bottom pressure for monitoring the large-scale, deep-ocean circulation
We show how, by focusing on bottom pressure measurements particularly on the global continental slope, it is possible to avoid the “fog” of mesoscale variability which dominates most observables in the deep ocean. This makes it possible to monitor those aspects of the ocean circulation which are most important for global scale ocean variability and climate. We therefore argue that such measurements should be considered an important future component of the Global Ocean Observing System, to complement the present open-ocean and coastal elements. Our conclusions are founded on both theoretical arguments, and diagnostics from a fine-resolution ocean model that has realistic amplitudes and spectra of mesoscale variability. These show that boundary pressure variations are coherent over along-slope distances of tens of thousands of kilometres, for several vertical modes. We illustrate the value of this in the model Atlantic, by determining the time for boundary and equatorial waves to complete a circuit of the northern basin (115 and 205 days for the first and second vertical modes), showing how the boundary features compare with basin-scale theoretical models, and demonstrating the ability to monitor the meridional overturning circulation using these boundary measurements. Finally, we discuss applicability to the real ocean and make recommendations on how to make such measurements without contamination from instrumental drift
Multicentre analysis of incidental findings on low-resolution CT attenuation correction images : an extended study
Objective: To review new incidental findings detected
on low-resolution CT attenuation correction (CTAC)
images acquired during single-photon emission CT-CT
myocardial perfusion imaging as an extension to our
initial study.
Methods: CTAC images acquired as part of myocardial
perfusion imaging performed using single-photon emission
CT at four UK nuclear medicine centres were evaluated as
part of a multicentre study. New incidental findings that
were considered to be clinically significant were evaluated
further. Positive-predictive value (PPV) was determined at
the time of definitive diagnosis.
Results: Out of 3485 patients, 962 (28%) patients had
a positive finding on the CTAC image, of which 824 (24%)
were new findings. 84 (2.4%) patients had findings
that were considered clinically significant at the time of
the CTAC report and which had not been previously
diagnosed. However, only 10 (0.29%) of these had
findings that were confirmed as clinically significant, with
the potential to be detrimental to patient outcome, after
follow-up and definitive diagnosis.
Conclusion: The overall PPV from all centres over the
2-year period was 12%. Each centre achieved what we
considered to be low PPVs with no significant difference
between the present and initial studies. The additional
data from the combined studies show that, statistically,
there is no significant difference between the PPVs from
any of the centres. We conclude that routine reporting of
CTAC images is not beneficial.
Advances in knowledge: This study combined with the
previous study offers a unique evaluation of new clinically
significant incidental findings on low-resolution CT images
in an attempt to determine the benefit of reporting the
CTAC images
Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART randomised, open-label trial
Background
Findings from the RESTART trial suggest that starting antiplatelet therapy might reduce the risk of recurrent symptomatic intracerebral haemorrhage compared with avoiding antiplatelet therapy. Brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases (such as cerebral microbleeds) are associated with greater risks of recurrent intracerebral haemorrhage. We did subgroup analyses of the RESTART trial to explore whether these brain imaging features modify the effects of antiplatelet therapy
Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial
Background:
Antiplatelet therapy reduces the risk of major vascular events for people with occlusive vascular disease, although it might increase the risk of intracranial haemorrhage. Patients surviving the commonest subtype of intracranial haemorrhage, intracerebral haemorrhage, are at risk of both haemorrhagic and occlusive vascular events, but whether antiplatelet therapy can be used safely is unclear. We aimed to estimate the relative and absolute effects of antiplatelet therapy on recurrent intracerebral haemorrhage and whether this risk might exceed any reduction of occlusive vascular events.
Methods:
The REstart or STop Antithrombotics Randomised Trial (RESTART) was a prospective, randomised, open-label, blinded endpoint, parallel-group trial at 122 hospitals in the UK. We recruited adults (≥18 years) who were taking antithrombotic (antiplatelet or anticoagulant) therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage, discontinued antithrombotic therapy, and survived for 24 h. Computerised randomisation incorporating minimisation allocated participants (1:1) to start or avoid antiplatelet therapy. We followed participants for the primary outcome (recurrent symptomatic intracerebral haemorrhage) for up to 5 years. We analysed data from all randomised participants using Cox proportional hazards regression, adjusted for minimisation covariates. This trial is registered with ISRCTN (number ISRCTN71907627).
Findings:
Between May 22, 2013, and May 31, 2018, 537 participants were recruited a median of 76 days (IQR 29–146) after intracerebral haemorrhage onset: 268 were assigned to start and 269 (one withdrew) to avoid antiplatelet therapy. Participants were followed for a median of 2·0 years (IQR [1·0– 3·0]; completeness 99·3%). 12 (4%) of 268 participants allocated to antiplatelet therapy had recurrence of intracerebral haemorrhage compared with 23 (9%) of 268 participants allocated to avoid antiplatelet therapy (adjusted hazard ratio 0·51 [95% CI 0·25–1·03]; p=0·060). 18 (7%) participants allocated to antiplatelet therapy experienced major haemorrhagic events compared with 25 (9%) participants allocated to avoid antiplatelet therapy (0·71 [0·39–1·30]; p=0·27), and 39 [15%] participants allocated to antiplatelet therapy had major occlusive vascular events compared with 38 [14%] allocated to avoid antiplatelet therapy (1·02 [0·65–1·60]; p=0·92).
Interpretation:
These results exclude all but a very modest increase in the risk of recurrent intracerebral haemorrhage with antiplatelet therapy for patients on antithrombotic therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage. The risk of recurrent intracerebral haemorrhage is probably too small to exceed the established benefits of antiplatelet therapy for secondary prevention
Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial
Background:
Antiplatelet therapy reduces the risk of major vascular events for people with occlusive vascular disease, although it might increase the risk of intracranial haemorrhage. Patients surviving the commonest subtype of intracranial haemorrhage, intracerebral haemorrhage, are at risk of both haemorrhagic and occlusive vascular events, but whether antiplatelet therapy can be used safely is unclear. We aimed to estimate the relative and absolute effects of antiplatelet therapy on recurrent intracerebral haemorrhage and whether this risk might exceed any reduction of occlusive vascular events.
Methods:
The REstart or STop Antithrombotics Randomised Trial (RESTART) was a prospective, randomised, open-label, blinded endpoint, parallel-group trial at 122 hospitals in the UK. We recruited adults (≥18 years) who were taking antithrombotic (antiplatelet or anticoagulant) therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage, discontinued antithrombotic therapy, and survived for 24 h. Computerised randomisation incorporating minimisation allocated participants (1:1) to start or avoid antiplatelet therapy. We followed participants for the primary outcome (recurrent symptomatic intracerebral haemorrhage) for up to 5 years. We analysed data from all randomised participants using Cox proportional hazards regression, adjusted for minimisation covariates. This trial is registered with ISRCTN (number ISRCTN71907627).
Findings:
Between May 22, 2013, and May 31, 2018, 537 participants were recruited a median of 76 days (IQR 29–146) after intracerebral haemorrhage onset: 268 were assigned to start and 269 (one withdrew) to avoid antiplatelet therapy. Participants were followed for a median of 2·0 years (IQR [1·0– 3·0]; completeness 99·3%). 12 (4%) of 268 participants allocated to antiplatelet therapy had recurrence of intracerebral haemorrhage compared with 23 (9%) of 268 participants allocated to avoid antiplatelet therapy (adjusted hazard ratio 0·51 [95% CI 0·25–1·03]; p=0·060). 18 (7%) participants allocated to antiplatelet therapy experienced major haemorrhagic events compared with 25 (9%) participants allocated to avoid antiplatelet therapy (0·71 [0·39–1·30]; p=0·27), and 39 [15%] participants allocated to antiplatelet therapy had major occlusive vascular events compared with 38 [14%] allocated to avoid antiplatelet therapy (1·02 [0·65–1·60]; p=0·92).
Interpretation:
These results exclude all but a very modest increase in the risk of recurrent intracerebral haemorrhage with antiplatelet therapy for patients on antithrombotic therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage. The risk of recurrent intracerebral haemorrhage is probably too small to exceed the established benefits of antiplatelet therapy for secondary prevention
Effect of remote ischaemic conditioning on clinical outcomes in patients with acute myocardial infarction (CONDI-2/ERIC-PPCI): a single-blind randomised controlled trial.
BACKGROUND: Remote ischaemic conditioning with transient ischaemia and reperfusion applied to the arm has been shown to reduce myocardial infarct size in patients with ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PPCI). We investigated whether remote ischaemic conditioning could reduce the incidence of cardiac death and hospitalisation for heart failure at 12 months. METHODS: We did an international investigator-initiated, prospective, single-blind, randomised controlled trial (CONDI-2/ERIC-PPCI) at 33 centres across the UK, Denmark, Spain, and Serbia. Patients (age >18 years) with suspected STEMI and who were eligible for PPCI were randomly allocated (1:1, stratified by centre with a permuted block method) to receive standard treatment (including a sham simulated remote ischaemic conditioning intervention at UK sites only) or remote ischaemic conditioning treatment (intermittent ischaemia and reperfusion applied to the arm through four cycles of 5-min inflation and 5-min deflation of an automated cuff device) before PPCI. Investigators responsible for data collection and outcome assessment were masked to treatment allocation. The primary combined endpoint was cardiac death or hospitalisation for heart failure at 12 months in the intention-to-treat population. This trial is registered with ClinicalTrials.gov (NCT02342522) and is completed. FINDINGS: Between Nov 6, 2013, and March 31, 2018, 5401 patients were randomly allocated to either the control group (n=2701) or the remote ischaemic conditioning group (n=2700). After exclusion of patients upon hospital arrival or loss to follow-up, 2569 patients in the control group and 2546 in the intervention group were included in the intention-to-treat analysis. At 12 months post-PPCI, the Kaplan-Meier-estimated frequencies of cardiac death or hospitalisation for heart failure (the primary endpoint) were 220 (8·6%) patients in the control group and 239 (9·4%) in the remote ischaemic conditioning group (hazard ratio 1·10 [95% CI 0·91-1·32], p=0·32 for intervention versus control). No important unexpected adverse events or side effects of remote ischaemic conditioning were observed. INTERPRETATION: Remote ischaemic conditioning does not improve clinical outcomes (cardiac death or hospitalisation for heart failure) at 12 months in patients with STEMI undergoing PPCI. FUNDING: British Heart Foundation, University College London Hospitals/University College London Biomedical Research Centre, Danish Innovation Foundation, Novo Nordisk Foundation, TrygFonden
Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial
BACKGROUND: Antiplatelet therapy reduces the risk of major vascular events for people with occlusive vascular disease, although it might increase the risk of intracranial haemorrhage. Patients surviving the commonest subtype of intracranial haemorrhage, intracerebral haemorrhage, are at risk of both haemorrhagic and occlusive vascular events, but whether antiplatelet therapy can be used safely is unclear. We aimed to estimate the relative and absolute effects of antiplatelet therapy on recurrent intracerebral haemorrhage and whether this risk might exceed any reduction of occlusive vascular events. METHODS: The REstart or STop Antithrombotics Randomised Trial (RESTART) was a prospective, randomised, open-label, blinded endpoint, parallel-group trial at 122 hospitals in the UK. We recruited adults (≥18 years) who were taking antithrombotic (antiplatelet or anticoagulant) therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage, discontinued antithrombotic therapy, and survived for 24 h. Computerised randomisation incorporating minimisation allocated participants (1:1) to start or avoid antiplatelet therapy. We followed participants for the primary outcome (recurrent symptomatic intracerebral haemorrhage) for up to 5 years. We analysed data from all randomised participants using Cox proportional hazards regression, adjusted for minimisation covariates. This trial is registered with ISRCTN (number ISRCTN71907627). FINDINGS: Between May 22, 2013, and May 31, 2018, 537 participants were recruited a median of 76 days (IQR 29-146) after intracerebral haemorrhage onset: 268 were assigned to start and 269 (one withdrew) to avoid antiplatelet therapy. Participants were followed for a median of 2·0 years (IQR [1·0- 3·0]; completeness 99·3%). 12 (4%) of 268 participants allocated to antiplatelet therapy had recurrence of intracerebral haemorrhage compared with 23 (9%) of 268 participants allocated to avoid antiplatelet therapy (adjusted hazard ratio 0·51 [95% CI 0·25-1·03]; p=0·060). 18 (7%) participants allocated to antiplatelet therapy experienced major haemorrhagic events compared with 25 (9%) participants allocated to avoid antiplatelet therapy (0·71 [0·39-1·30]; p=0·27), and 39 [15%] participants allocated to antiplatelet therapy had major occlusive vascular events compared with 38 [14%] allocated to avoid antiplatelet therapy (1·02 [0·65-1·60]; p=0·92). INTERPRETATION: These results exclude all but a very modest increase in the risk of recurrent intracerebral haemorrhage with antiplatelet therapy for patients on antithrombotic therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage. The risk of recurrent intracerebral haemorrhage is probably too small to exceed the established benefits of antiplatelet therapy for secondary prevention. FUNDING: British Heart Foundation
Antarctic circumpolar transport and the southern mode: a model investigation of interannual to decadal timescales
It is well-established that, at periods shorter than a year, variations in Antarctic Circumpolar Transport are reflected in a barotropic mode, known as the Southern Mode, in which sea level and bottom pressure varies coherently around Antarctica. Here, we use two multidecadal ocean model runs to investigate the behaviour of the Southern Mode at time scales on which density changes become important, leading to a baroclinic component to the adjustment. We find that the concept of a Southern Mode in bottom pressure remains valid, and remains a direct measure of the circumpolar transport, with changes at the northern boundary playing only a small role even on decadal time scales. However, at periods longer than about 5 years, density changes start to play a role, leading to a surface intensification of the vertical profile of the transport. We also find that barotropic currents on the continental slope account for a significant fraction of the variability, and produce surface intensification in the meridional-integral flow. The role of density variations results in a sea level signal which, although reflecting transport changes at all time scales, has a ratio of sea level to transport which becomes larger at longer time scales. This means that any long-term transport monitoring strategy based on present measurement systems must involve multiplying the observed quantity by a factor which depends on frequency
Dosimetry and Microdosimetry onboard International Space Station for Radiobiology
PURPOSE:
Incidental findings, discovered in low-dose CT images obtained during hybrid imaging, are an increasing phenomenon with advancing CT technology. Understanding their diagnostic value along with technical limitations is therefore important when reporting images and recommending follow-up, which may result in additional radiation dose from further diagnostic imaging and an increase in patient anxiety. This study assesses lesion detection in CT images obtained during attenuation correction (AC) acquisitions on two SPECT/CT systems.
METHODS:
An anthropomorphic chest phantom, containing simulated lesions of varying size and density, was imaged on a GE Infinia Hawkeye 4 and a Siemens Symbia T6 with low-dose CT settings used during AC acquisitions in myocardial perfusion imaging. Twenty-two readers completed a lesion detection task, assessing 46 images (15 normal, 31 abnormal containing 41 lesions) from each SPECT/CT system. Data was evaluated using a jackknife alternative free-response receiver operating characteristic (JAFROC) analysis.
RESULTS:
JAFROC analysis showed a significant difference (P < 0.0001) in lesion detection with figures of merit 0.599 (95% CI 0.568, 0.631) and 0.810 (95% CI 0.781, 0.839) for GE Infinia Hawkeye 4 and Siemens Symbia T6 respectively. Lesion detection on the Infinia Hawkeye 4 was generally limited to larger, higher density lesions. The Siemens Symbia T6 images allowed improved detection rates with mid-sized lesions and some lower density lesions. However, readers struggled to detect small (5mm) lesions on both image sets, irrespective of density.
CONCLUSION:
Lesion detection is more reliable in low-dose CT images from the Symbia T6 than those from the Infinia Hawkeye4. This phantom based study gives an indication of potential lesion detection in the clinical context as shown by two commonly used SPECT/CT systems, which may assist the clinician in determining if further diagnostic imaging is justified